Saturday, 31 October 2026European Markets

MKB Nedsense Stock Is 10% Up So Far Today

Loading stream...

(VIANEWS) - Shares of MKB Nedsense (AEX-Index: NEDSE.AS) jumped by a staggering 10.91% to €0.12 at 14:08 EST on Monday, after three sequential sessions in a row of losses. AEX-Index is falling 0.13% to €755.65, after five successive sessions in a row of losses. This seems, so far, a somewhat bearish trend exchanging session today.

MKB Nedsense's last close was €0.11, 28.1% below its 52-week high of €0.15.

About MKB Nedsense

MKB Nedsense N.V. engages in the finance and lending of money to natural persons and legal entities. It also provides guarantees and/or other securities towards third parties for its obligations and/or for obligations for companies in the investment portfolio. The company was formerly known as Nedsense Enterprises N.V. MKB Nedsense N.V. was founded in 1999 and is based in Bussum, the Netherlands.

Moving Average

MKB Nedsense's value is higher than its 50-day moving average of €0.12 and under its 200-day moving average of €0.13.

Yearly Top and Bottom Value

MKB Nedsense's stock is valued at €0.12 at 14:08 EST, way below its 52-week high of €0.15 and way above its 52-week low of €0.09.

Volume

Today's last reported volume for MKB Nedsense is 4748 which is 84.96% below its average volume of 31585.

More news about MKB Nedsense (NEDSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com